Particularly, conventional type 1 DCs (cDC1) are recognized as the most competent cells to activate CD8 T cells due to their enhanced ability to cross-present tumor antigens on MHC class I molecules [19,20,21,22]. This evidence concerns the gene CD8A and neoplasm.